Table 2 Patients’ serum samples.
From: Increased levels of circulating MMP3 correlate with severe rejection in face transplantation
Patient | Posttransplant month | Histological Banff grade | Status | Clinical presentation | MMP3 ELISA (ng/ml) | Rejection management |
|---|---|---|---|---|---|---|
Patient 1 | 12 | I | NR | NA | 6.04 | NA |
Patient 1 | 17 | II | NSR | erythema and edema, mucosa lesion | 14.37 | maintenance immunosuppression adjustment, topical therapy |
Patient 1 | 24 | 0 | NR | NA | 7.34 | NA |
Patient 1 | 30 | III | NSR | subclinical | 7.75 | maintenance immunosuppression adjustment |
Patient 1 | 42 | I | NR | NA | 7.3 | NA |
Patient 2 | 18 | 0 | NR | NA | 11.33 | NA |
Patient 2 | 23 | II | SR | erythema and edema | 70.77 | steroid bolus |
Patient 2 | 24 | III | SR | erythema and edema | 124.6 | ATG |
Patient 2 | 48 | III | SR | erythema and edema | 193.86 | steroid bolus |
Patient 2 | 54 | I | NR | NA | 20.47 | NA |
Patient 3 | 12 | 0 | NR | NA | 16.66 | NA |
Patient 3 | 18 | III | SR | exanthema | 79.14 | steroid bolus |
Patient 3 | 34 | III | SR | erythema | 24.53 | steroid bolus |
Patient 3 | 54 | 0 | NR | NA | 20.65 | NA |
Patient 4 | 6 | I | NR | NA | 21.96 | NA |
Patient 4 | 13 | III | NSR | erythema and edema | 18.03 | topical therapy |
Patient 4 | 18 | 0 | NR | NA | 29.84 | NA |
Patient 4 | 24 | III | NSR | erythema and edema | 39.43 | topical therapy |
Patient 5 | 6 | I | NR | NA | 31.31 | NA |
Patient 5 | 7 | III | SR | erythema and edema | 105.82 | steroid bolus, ATG, IVIG |
Patient 5 | 9 | I | NR | NA | 49.12 | NA |
Patient 5 | 12 | III | NSR | hyperpigmentation | 43.88 | maintenance immunosuppression adjustment, topical therapy |
Patient 6 | 3 | II | NR | NA | 45.92 | NA |
Patient 6 | 12 | 0 | NR | NA | 23.76 | NA |
